Fibrolamellar Carcinoma (FLC) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Fibrolamellar Carcinoma (FLC), a rare form of liver cancer typically found in individuals under 40 years old, is distinct from other liver cancers as it occurs in those with healthy livers. Its exact cause remains poorly understood, though recent studies suggest a chromosome 19 deletion resulting in an anomalous fusion of DNAJB1 and PRKACA genes may be pivotal in its development. Patients usually present with a sizable solitary liver mass alongside nonspecific symptoms. Histologically, FLC displays characteristic features such as large polygonal cells with oncocytic cytoplasm, prominent nucleoli, and dense collagen bands separating trabeculae and cords. Differential diagnosis distinguishes it from classical hepatocellular carcinoma and intrahepatic cholangiocarcinoma through immunohistochemical studies, including markers like cytokeratin 7, CD68, and HepPar-1. Furthermore, FLC is distinguished by the activation of protein kinase A. The prognosis for FLC resembles that of classical hepatocellular carcinoma without liver cirrhosis, heavily reliant on tumor resectability. Treatment options encompass liver transplant, chemotherapy, and hepatic artery embolization.
· FLC affects both genders and has an approximate incidence of 1 in 5,000,000 individuals in the general population.
Thelansis’s “Fibrolamellar Carcinoma (FLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fibrolamellar Carcinoma (FLC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Fibrolamellar Carcinoma (FLC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Fibrolamellar Carcinoma (FLC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Tags: Fibrolamellar Carcinoma (FLC), Fibrolamellar Carcinoma (FLC) market outlook, Fibrolamellar Carcinoma (FLC) competitive landscape, Fibrolamellar Carcinoma (FLC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
